Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Common Stock Repurchased

Cash spent buying back the company's own shares.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Common Stock Repurchased · Q3 FY2026 · quarter ended Sep 2026

Common stock repurchased outflow grows to $0

Q3 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0. Over 3 fiscal years it compounded at +1222.9% a year.

Context

  • Common stock repurchased amounted to 2.9% of revenue in FY2025, down 4.7 pp from a year earlier.
  • Common stock repurchased grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
-$125.02M-59.9% YoY
LTMSep 2026
$0+100.0% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-59.9%——
3-year CAGR+1222.9%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(125.02M) USD
Year-over-year change
+59.9%

Common Stock Repurchased vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's LTM Sep 2026 common stock repurchased of $0 is the 6th largest of the 9 companies compared; the peer median is $38.04M.
  • Its year-over-year change of +100.0% is the 2nd highest of 5, against a peer median of +41.1%.
  • Common stock repurchased amounts to 0.0% of revenue for JAZZ, versus a peer median of 1.5%.
JAZZ Competitors Peer median
Common Stock Repurchased for JAZZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TGTXTG Therapeutics, Inc.LTM Sep 2026$199.99M +104.4%—22.3%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$158.1M -66.2%—4.3%
GMABGenmab A/SLTM Jun 2026$119.92M —-22.0%2.9%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$75M ——25.8%
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$1.08M -17.8%—0.1%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$0 +100.0%+1222.9%0.0%
INCYIncyte CorporationLTM Jun 2026$0 +100.0%—0.0%
LEGNLegend Biotech CorporationLTM Sep 2026$0 ——0.0%
MGNXMacroGenics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding JAZZ) $38.04M+41.1%-22.0%1.5%

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(329.67M)(224.06M)414.83M560.12M(356.15M)
Depreciation & Amortization552.48M629.47M638.7M660.07M696.3M
Deferred Income Tax69.2M(292.25M)(260.22M)(208.33M)(444.97M)
Stock-Based Compensation189.01M222M226.84M248.05M291.13M
Change in Working Capital(47.95M)9.91M(204.44M)(76.72M)18.9M
Accounts Receivables(92.74M)(90.14M)(51.88M)(21.12M)(106.28M)
Inventory(48.86M)(49.64M)(13.42M)(45.54M)(86.04M)
Accounts Payables57.02M(11.23M)9.6M(20.07M)39.85M
Other Working Capital36.62M160.91M(148.74M)10.01M171.37M
Other Non-Cash Items345.44M926.92M276.29M212.72M1.15B
Operating Cash Flow778.51M1.27B1.09B1.4B1.36B
Capital Expenditures(45.53M)(498.19M)(23.96M)(48.07M)(209.75M)
Acquisitions (Net)(6.23B)53M00(858.05M)
Purchases of Investments(26.82M)(61.04M)(390.1M)(1.31B)(1.83B)
Sales of Investments1.1B60M270M845M1.36B
Other Investing Activities(17.89M)0(19M)(10M)(122.83M)
Investing Cash Flow(5.21B)(446.23M)(163.06M)(508.2M)(1.51B)
Debt Repayment3.87B(582.01M)(31M)374.77M(781M)
Common Stock Issued135.26M046.46M20.65M107.86M
Common Stock Repurchased0(54K)(269.76M)(311.43M)(125.02M)
Dividends Paid00000
Other Financing Activities(35.6M)(45.44M)(50.95M)(63.47M)(75.22M)
Financing Cash Flow3.97B(529.49M)(305.25M)20.52M(873.38M)
Effect of Forex Changes(3.21M)(6.22M)1.14M(1.68M)6.56M
Net Change in Cash(466.32M)290.03M624.83M906.55M(1.02B)
Free Cash Flow732.98M773.78M1.07B1.35B1.15B

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.